[go: up one dir, main page]

WO2013118986A1 - Triazolopyridine derivatives as a tyrosine kinase inhibitor - Google Patents

Triazolopyridine derivatives as a tyrosine kinase inhibitor Download PDF

Info

Publication number
WO2013118986A1
WO2013118986A1 PCT/KR2013/000539 KR2013000539W WO2013118986A1 WO 2013118986 A1 WO2013118986 A1 WO 2013118986A1 KR 2013000539 W KR2013000539 W KR 2013000539W WO 2013118986 A1 WO2013118986 A1 WO 2013118986A1
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
disease
compound
phenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2013/000539
Other languages
French (fr)
Inventor
Jae Yi Sim
Kyung Ik Lee
Ho Seok Kim
Tae Hee Ha
Kwee Hyun Suh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Priority to EP13747313.8A priority Critical patent/EP2812335A4/en
Priority to CN201380008333.2A priority patent/CN104093719A/en
Priority to CA2862718A priority patent/CA2862718A1/en
Priority to US14/376,562 priority patent/US20140364438A1/en
Priority to BR112014017701A priority patent/BR112014017701A8/en
Priority to AU2013218539A priority patent/AU2013218539A1/en
Priority to MX2014009524A priority patent/MX2014009524A/en
Priority to JP2014556473A priority patent/JP2015506974A/en
Priority to IN7266DEN2014 priority patent/IN2014DN07266A/en
Priority to HK15102187.2A priority patent/HK1201824A1/en
Priority to RU2014136170A priority patent/RU2014136170A/en
Publication of WO2013118986A1 publication Critical patent/WO2013118986A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Definitions

  • the present invention relates to novel triazolopyridine derivatives having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same as an active ingredient.
  • a protein kinase is an enzyme that modifies other proteins by chemically adding phosphate groups to a specific residue thereof via phosphorylation.
  • the human genome contains about 500 protein kinase genes and they constitute about 2% of all human genes.
  • protein kinases can be classified into three types depending on their substrates: serine/threonine-specific protein kinases which phosphorylate serine and/or threonine residues, tyrosine-specific protein kinases which phosphorylate tyrosine residues, and protein kinases which phosphorylate tyrosine and serine/threonine residues.
  • Protein kinases play a key role in mediation of signal transduction from a cell surface to a nucleus in response to a variety of extracellular stimuli. They regulate several physiological and pathological cellular phenomena, including cell division, proliferation, differentiation, apoptosis, cell mobility, mitogenesis, etc., and hence they are closely related with various diseases.
  • kinase-related diseases are: autoimmune disorders such as atopic dermatitis, asthma, rheumatoid arthritis, Crohn's disease, psoriasis, Crouzon syndrome, achondroplasia, and thanatophoric dysplasia; cancer such as prostate cancer, colorectal cancer, breast cancer, brain and throat cancer, leukemia and lymphoma; diabetes; restenosis; atherosclerosis; renal and hepatic fibrosis; myeloproliferative disorder and lymphoproliferative disorder; and eye disease.
  • autoimmune disorders such as atopic dermatitis, asthma, rheumatoid arthritis, Crohn's disease, psoriasis, Crouzon syndrome, achondroplasia, and thanatophoric dysplasia
  • cancer such as prostate cancer, colorectal cancer, breast cancer, brain and throat cancer, leukemia and lymphoma
  • diabetes restenosis
  • atherosclerosis atherosclerosis
  • T-cells or T- lymphocytes
  • B-cells or B-lymphocytes
  • T-cells mediate signal transduction by receiving signals from antigen-presenting cells through T-cell receptor (TCR) located on the surface of the cell which activates various kinases such as Janus kinase (JA ) so as to forward the signal to effectors.
  • TCR T-cell receptor
  • JAK proteins as tyrosine kinases, may be activated by hematopoietic cytokine as well as interferon, and this process can regulate the activation of transcriptional regulators, STAT proteins.
  • Therapeutic possibilities based on the inhibition (or promotion) of JAK/STAT pathway may provide a potent medication in the field of immunomodulation.
  • JAK3 is believed to be implicated in inflammation as it is expressed only in T-cells and activated by IL-2.
  • JAK2 which participates in hemopoietic activity and red blood cell homeostasis or JAKl which can be expressed in different types of tissues
  • JAK3 is mostly expressed in lymphocytes and plays a very important role in signaling by using various cytokines including IL-2, IL-4, IL-7, IL-9, IL-15 and the like, and therefore JAK3 is getting more attention in respect of side effects (Flanagan et al., Journal of Medicinal Chemistry, 53, 8468, 2010).
  • JAK3 plays an important role not only in maturation of B-cells and T-cells, but also in maintenance of functions of T-cells. Therefore, a JAK inhibitor, especially JAK3 inhibitor, may be useful for treatment of autoimmune disorders such as rheumatoid arthritis, psoriasis, atopic dermatitis, lupus, multiple sclerosis, Type I diabetes and diabetic complications, cancer, asthma, thyroid autoimmune disease, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia, etc.
  • autoimmune disorders such as rheumatoid arthritis, psoriasis, atopic dermatitis, lupus, multiple sclerosis, Type I diabetes and diabetic complications, cancer, asthma, thyroid autoimmune disease, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia, etc.
  • BTK Bruton's tyrosine kinase
  • XLA X-linked Agammaglobulinemia
  • XID mouse X-linked immunodeficiency
  • BTK is a nonreceptor protein tyrosine kinase (NRPTK) which participates in controlling signal transduction pathway, growth and differentiation of B- lymphocytes.
  • BTK is a key regulator of B-cell development, activation, signaling, and survival (Kurosaki, Curr. Op. 1mm., 276-281, 2000; and Schaeffer and Schwartzberg, Curr. Op. lmm., 282-288, 2000].
  • BTK plays a role in a number of other hematopoietic cell signaling pathways, e.g., toll-like receptor (TLR)- or cytokine receptor-mediated TNF-a production in macrophages, IgE receptor (FcepsilonRi) signaling in mast cells, inhibition of Fas/APO-1 apoptotic signaling in B-lymphocytes, and collagen-stimulated platelet aggregation.
  • TLR toll-like receptor
  • FcepsilonRi IgE receptor
  • BTK participates in signal transduction pathways initiated by the binding of a variety of extracellular ligands to their cell surface receptors.
  • BCR B-cell antigen receptor
  • BTK activation by the concerted actions of protein tyrosine kinases Lyn and Syk is required for induction of phospholipase C-y2-mediated calcium mobilization (Kurosaki, T., Curr. Opin. Immunol., 9, 309-318, 1997). Therefore, inhibition of BTK can become a useful therapeutic option since it prevents the development of B-cell mediated diseases.
  • BTK deficient mice have been shown to be resistant to disease manifestations in collagen-induced arthritis, and BTK inhibitor is known to be effective against collagen-induced arthritis in mice dose-dependently (Jansson and Holmdahl, Clin. Exp. Immunol., 94, 459, 1993; and Pan et al., Chem. Med Chem., 2, 58, 2007). Therefore, an effective BTK inhibitor may be useful for treatment of rheumatoid arthritis.
  • inhibition of BTK activation can be useful for treatment of autoimmune disease and/or inflammatory disease and/or allergic disease, e.g., systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis, osteoarthritis, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, multiple sclerosis, ankylosing spondylitis, angiitis, inflammatory bowel disease, psoriasis, alopecia universalis, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, allergy, allergic conjunctivitis, allergic rhinitis, atopic dermatitis, and asthma, but not limited thereto.
  • SLE systemic lupus erythematosus
  • ITP idiopathic thrombocytopenic purpura
  • myasthenia gravis allergy, allergic conjunctivitis, allergic rhin
  • BTK regulates apoptosis in cells
  • inhibition of BTK activation can be used to treat B-cell lymphoma and leukemia as well.
  • Janus kinases such as JAK3 and TEC kinases
  • BTK play important roles in activation of T-cell and/or B-cell that are closely related with development of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproferative diseases and immunologically mediated diseases.
  • development of an effective inhibitor of such kinases may lead to discovery of potent drug for treatment of various inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, and immunologically mediated diseases.
  • Tofacitinib (CP-690550), as an inhibitor of JAK3, is in development as an oral drug by Pfizer and a phase III trial is under way.
  • PCI- 32765 (Pharmacyclics), as an inhibitor of BTK, is in phase I clinical trial stage; however, it has been reported that the drug could activate a different target, accompanied by adverse side effects including skin rash and diarrhea. Therefore, there is a strong need for a novel drug which can inhibit Janus kinases and TEC kinases in a safe and effective manner.
  • T- lymphocytes and/or B- lymphocytes abnormally activated lymphocytes
  • JAK3 Janus kinases
  • TEC kinases such as BTK (Burton's tyrosine kinase), ITK (IL2-inducible T-cell kinase), BMX (bone marrow tyrosine kinase), RLK (resting lymphocyte kinase) and the like.
  • It is another object of the present invention to provide a pharmaceutical composition comprising the compound for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.
  • X is O, NH, CH 2 , S, SO or SO 2 ;
  • Y is phenyl or pyridyl; n is an integer ranging from 0 to 4;
  • Rl is each independently hydrogen, C 1-6 alkoxy or di(C]_ 6 alkyl)aminomethyl
  • W is phenyl, pyridyl, or phenyl substituted with one or more substituents selected from the group consisting of hydrogen, halogen, hydroxy, amino, C], 6 alkylamino, Ci -6 alkylheterocyclylamino, di(Ci -6 alkyl)aminoCi -6 alkyl, heterocycle, hydroxy heterocycle, Ci. 6 alkylheterocycle, hydroxyC 1-6 alkylheterocycle, C]. 6 alkoxyC 1-6 alkylheterocycle, heterocyclylcarbonyl, and heterocyclylC t . 6 alkylcarbonyl, wherein the heterocycle is a saturated 3- to 8-membered monocyclic hetero ring independently containing one or more of heteroatoms selected from N, O and S.
  • a pharmaceutical composition for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • a method for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors in an animal comprising the step of administering to the animal an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • novel triazolopyridine derivatives in accordance with the present invention can selectively and effectively inhibit kinases that are mostly expressed in abnormally activated lymphocytes (T-lymphocytes and/or B-lymphocytes) including Janus kinases such as JAK3 as well as TEC kinases such as BTK, ITK, BMX and RLK and the like.
  • T-lymphocytes and/or B-lymphocytes abnormally activated lymphocytes
  • Janus kinases such as JAK3
  • TEC kinases such as BTK, ITK, BMX and RLK and the like.
  • novel triazolopyridine derivatives as a tyrosine kinase inhibitor in accordance with the present invention may be useful for prevention or treatment of diseases that are mediated by abnormally activated T-lymphocytes, B-lymphocytes or both, such as inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors.
  • diseases that are mediated by abnormally activated T-lymphocytes, B-lymphocytes or both such as inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors.
  • substituent W may be selected from the group consisting of Wl to W18, preferably W2, W4, W9, W12 or W17, but not limited thereto.
  • X, Y, Z and W are the same as defined above.
  • reaction processes are exemplified in the following stepwise reaction.
  • the compound of formula (9) is, for example, subjected to a condensation reaction with the compound of formula (8) under dichloromethane condition to yield a condensed compound of formula (7). Then, hydroxy lamine hydrochloride and diisopropylethylamine may be added to a solvent such as a mixed solvent of methanol and ethanol, followed by addition of the compound of formula (7) prepared above to obtain a compound of formula (6).
  • a solvent such as a mixed solvent of methanol and ethanol
  • the compound of formula (6) is allowed to react with X-Y-NO 2 (e.g., 3-fluoronitrobenzene) in an organic solvent such as NN-dimethylformamide, NN-dimethylacetamide or N-methylpyrrolidine in the presence of an inorganic base such as cesium carbonate, sodium carbonate or potassium carbonate at 140 to 150°C with stirring to obtain a compound of formula (5) containing a nitro group.
  • an organic base such as cesium carbonate, sodium carbonate or potassium carbonate
  • Copper bromide and bromic acid are added to the compound of formula (5), followed by dropwise addition of an aqueous solution of sodium nitrite at -10 to 0°C to obtain a compound of formula (4) containing a bromine group.
  • the compound of formula (4) prepared above may be reacted with W-NH 2 in an organic solvent such as 1 ,4-dioxane in the presence of a palladium catalyst or trifluoroacetic acid at 100 to 110°C for 8 hours with stirring to obtain a compound of formula (3) containing a W-NH 2 group.
  • the nitro group of the compound of formula (3) may be converted to an amino group by subjecting the compound to an iron-mediated reduction reaction or a hydrogenation reaction using palladium/carbon as a catalyst to obtain an aniline compound of formula (2).
  • the compound of formula (2) may be allowed to react with an acryloyl chloride substituted with Rl in an organic solvent such as dichloromethane or tetrahydrofuran, or a mixed solvent such as an aqueous solution of 50% tetrahydrofuran in the presence of an inorganic base such as sodium bicarbonate or an organic base such as triethylamine or diisopropylethylamine at a low temperature ranging from -10°C to 10°C; or with an acrylic acid substituted with Rl by employing a binder such as l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDCI) or 2-(lH-7-azabenzotriazol-l-yl)- 1,1,3,3-tetramethyl uronium hexafluorophosphate mefhanaminium (HATU) in pyridine, to obtain a desired compound of formula (1) of the present invention containing an acrylamide group
  • the compound of formula (I) in the present invention may also form a pharmaceutically acceptable inorganic or organic acid addition salts.
  • Such salts are acid addition salts formed by acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid and the like.
  • the pharmaceutically acceptable salt in the present invention can be prepared by dissolving the compound of formula (I) in a water-miscible organic solvent, e.g., acetone, methanol, ethanol or acetonitrile, followed by adding an organic or inorganic acid, and filtering the precipitated crystal. Also, it may be prepared by removing a solvent or an excessive amount of acid from the acid-added reaction mixture under reduced pressure, followed by drying the residue, or conducting eduction using a different organic solvent, and then filtering the precipitated salt.
  • a water-miscible organic solvent e.g., acetone, methanol, ethanol or acetonitrile
  • the compound of formula (I) or a pharmaceutically acceptable salt thereof in the present invention may be in the form of solvates or hydrates, and such compounds are also included within the scope of the present invention.
  • the compound of formula (I) or a pharmaceutically acceptable salt thereof in the present invention can selectively and effectively inhibit a protein kinase.
  • such compound can selectively and effectively inhibit kinases that are mostly expressed in abnormally activated lymphocytes (T- lymphocytes and/or B- lymphocytes) including Janus kinase 3 (JAK3), Bruton's tyrosine kinase (BTK), IL-2 inducing T-cell kinase (ITK), resting lymphocyte kinase (RLK) and bone marrow tyrosine kinase (BMX), and thus, may be useful for prevention or treatment of diseases that are mediated by abnormally activated B-lymphocytes, T-lymphocytes or both, such as inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors.
  • diseases that are mediated by abnormally activated B-lymphocytes, T-
  • the present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors, which comprises the compound of formula (I) or its pharmaceutically acceptable salt as an active ingredient.
  • inflammatory diseases examples include arthritis, rheumatoid arthritis, spondyloarthropathy, gouty arthritis, osteoarthritis, juvenile arthritis, other arthritic conditions, lupus, systemic lupus erythematosus (SLE), skin-related diseases, psoriasis, eczema, dermatitis, atopic dermatitis, pain, pulmonary disorder, lung inflammation, adult respiratory distress syndrome (ARDS), pulmonary sarcoidosis, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD), cardiovascular disease, artherosclerosis, myocardial infarction, congestive heart failure, cardiac reperfusion injury, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, asthma, Sjogren's syndrome, autoimmune thyroid disease, urticaria
  • examples of said cancer and tumor may be selected from the group consisting of liver cancer, hepatocellular carcinoma, thyroid cancer, colorectal cancer, testicular cancer, bone cancer, oral cancer, basal cell carcinoma, ovarian cancer, brain tumor, gallbladder carcinoma, biliary tract cancer, head and neck cancer, vesical carcinoma, tongue cancer, esophageal cancer, glioma, glioblastoma, renal cancer, malignant melanoma, gastric cancer, breast cancer, sarcoma, pharynx carcinoma, uterine cancer, cervical cancer, prostate cancer, rectal cancer, pancreatic cancer, lung cancer, skin cancer and other solid tumor, but not limited thereto.
  • the compound of formula (I) or a pharmaceutically acceptable salt thereof in the present invention may be used in combination with other drugs to enhance efficacy in treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, or immunologically mediated diseases.
  • Examples of the drug which may be used in combination with the inventive compound or a pharmaceutically acceptable salt thereof for treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, or immunologically mediated diseases are one or more of drugs selected from the group consisting of steroids (prednisone, prednisolone, methylprednisolone, cortisone, hydroxycortisone, betamethasone, dexamethasone, etc.), methotrexate, lefluonomide, anti-TNFa agents (etanercept, infliximab, adalimumab, etc.), calcineurin inhibitors (tacrolimus, pimecrolimus, etc.) and anti-histamines (diphenhydramine, hydroxyzine, loratadine, ebastine, ketotifen, cetirizine, levocetirizine, fexofenadine, etc.), but not limited thereto.
  • steroids pred
  • Examples of the drug which may be used in combination with the inventive compound or its pharmaceutically acceptable salt for treatment of cancers or tumors include one or more selected from the group consisting of: cell signal transduction inhibitors (glivec, iressa, tarceva, etc.), mitosis inhibitors (vincristine, vinblastine, etc.), alkylating agents (cyclophosphamide, thiotepa, busulfan, etc.), anti-metabolites (tagafur, methotrexate, gemcitabine, etc.), topoisomerase inhibitors (irinotecan, topotecan, amsacrine, etoposide, teniposide, etc.), immunotherapeutic agents (interferon ⁇ , ⁇ , ⁇ , interleukin, etc.) and anti- hormonal agents (tamoxifen, leuprorelin, anastrozole, etc.), but not limited thereto.
  • cell signal transduction inhibitors glivec, iressa, tarceva,
  • the inventive compound or a pharmaceutically acceptable salt thereof may be administered orally or parenterally as an active ingredient in an effective amount ranging from about 0.1 to 2,000 mg/day, preferably 1 to 1,000 mg/day, 1 to 4 times daily or on/off schedule in case of a human (of approximately 70 kg body weight) in a single dose or in divided doses.
  • the dosage of the active ingredient may be adjusted in light of various relevant factors such as the condition of the subject to be treated, type and seriousness of illness, administration rate, and opinion of doctor. In certain cases, an amount less than the above dosage may be suitable. An amount greater than the above dosage may be used unless it causes deleterious side effects and such amount can be administered in divided doses per day.
  • the pharmaceutical composition of the present invention may typically comprise pharmaceutically acceptable additives, carriers or excipients.
  • the pharmaceutical composition of the present invention may be formulated in accordance with conventional methods, and may be prepared in the form of oral formulations such as tablets, pills, powders, capsules, syrups, emulsions, microemulsions and others, or parenteral formulations such as intramuscular, intravenous or subcutaneous administrations.
  • carriers or additives such as cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspending agents, emulsifiers, diluents, and others may be used.
  • carriers or additives such as water, saline, glucose solution, glucose solution analogs, alcohols, glycols, ethers (e.g., polyethylene glycol 400), oils, fatty acids, fatty acid esters, glycerides, surfactants, suspending agents, emulsifiers, and others may be used.
  • the present invention provides a method for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors in an animal, comprising the step of administering to the animal an effective amount of the compound of formula (I) or its pharmaceutically acceptable salt.
  • the present invention provides a use of the compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors.
  • the compound of formula (I) of the present invention may be used for the study of biological and pathological phenomena of a kinase, the study of intracellular signaling pathway mediated by a kinase as well as comparative evaluation with new kinase inhibitors.
  • Example 1 Preparation of ⁇ -(S-il-i ⁇ i ⁇ meth lpiperazin-l- phenylamino)- [l,2,4]triazolo[l,5-a]pyridin-8-yloxy)phenyl)acrylamide
  • N,N-dimethylformamide (30 mL) was added to the compound obtained in Step 2 (3.2 g, 0.021 mol).
  • 3-fluoronitrobenzene (2.7 mL, 0.026 mol) and cesium carbonate (13.9 g, 0.043 mol) was added to the reaction solution.
  • the resulting mixture was stirred for 6 hours at 150°C, and then washed with dichloromethane, distilled water and an aqueous solution of ammonium chloride.
  • the organic layer was separated, dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure.
  • 1,4-dioxane (30 n L) was added to a mixture of the compound obtained in
  • Step 4 (1.8 g, 0.005 mol) and 4-(4-methylpiperazin-l-yl)aniline (1.03 g, 0.005 mol).
  • Tris(dibenzylideneacetone)dipalladium(0) (0.49 g, 0.001 mol) and 2,2'- bis(diphenylphosphino)-l,l '-binaphthyl (0.33 g, 0.001 mol) were added to the mixture, followed by stirring for 5 minutes at room temperature.
  • Cesium carbonate (3.5 g, 0.011 mol) was added to the reaction mixture, followed by stirring for 8 hours at 100°C.
  • Step 7) Preparation of N-(3-((2-((4-(4-methv iperazin-l- yl)phenvnamino -ri,2,41triazolorL5-alpyridin-8-yl)oxy phenvnacrylamide
  • Tetrahydrofuran (10 mL) and distilled water (2 mL) were added to the compound obtained in Step 6 (0.76 g, 0.002 mol) and sodium bicarbonate (0.46g, 0.006 mol).
  • Acryloyl chloride (0.18 mL, 0.002 mol) was added slowly dropwise to the reaction solution at 0°C, followed by stirring for 2 hours at room temperature.
  • Steps 5, 6 and 7 of Example 1 were repeated in sequence, except for using the compound obtained in Step 4 (0.21 g, about 0.001 mol) and 2-fluoro-N 1 -(l-methylpiperidin-4-yl)benzene-l,4-diamine (0.14 g, 0.001 mol) to obtain the title compound (0.1 g, yield: 32%).
  • Steps 5, 6 and 7 of Example 1 were repeated in sequence, except for using the compound obtained in Step 4 (0.45 g, 0.001 mol) and 4-((dimethylamino)methyl)aniline (0.2 g, 0.001 mol) to obtain the title compound (0.11 g, yield: 23%).
  • Steps 5, 6 and 7 of Example 1 were repeated in sequence, except for using the compound obtained in Step 4 (0.35 g, 0.001 mol) and (4-aminophenyl)(4-methylpiperazin-l-yl)methanone (0.23 g, 0.001 mol) to obtain the title compound (0.13 g, yield: 25%).
  • Steps 5, 6 and 7 of Example 1 were repeated in sequence, except for using the compound obtained in Step 4 (0.37 g, 0.001 mol) and 4-(4-isopropylpiperazin) (0.24 g, 0.001 mol) to obtain the title compound (0.15 g, yield: 27%).
  • single tablets for oral administration comprising each of the compounds of formula (I) obtained in Examples 1 to 5 as an active ingredient were prepared based on the composition and amount shown in Table 1.
  • hard gelatin capsules for oral administration comprising each of the compounds of formula (I) obtained in Examples 1 to 5 as an active ingredient were prepared based on the composition and amount shown in Table 2. [Table 2]
  • injectable formulations comprising each of the compounds of formula (I) obtained in Examples 1 to 5 as an active ingredient were prepared based on the composition and amount shown in Table 3, wherein when a salt of the compound of formula (I) was used, the pH value was not adjusted.
  • injectable formulations comprising each of the compounds of formula (I) obtained in Examples 1 to 5 as an active ingredient were prepared based on the composition and amount shown in Table 4.
  • Test Example 1 Evaluation of JAK3 and BTK Inhibitory Activity
  • the compounds prepared in Examples 1 to 5 were tested for JAK3 and BTK kinase inhibitory activity.
  • Kinase inhibitory activity was measured by using Z-Lyte Kinase Assay Kit (Invitrogen), and JAK3 and BTK enzymes were purchased from Invitrogen (PV3855, PV3190).
  • the compounds of Examples 1 to 5 were diluted with an aqueous solution of 4% DMSO to obtain solutions with concentrations in the range of 1 to 0.0001 ⁇ .
  • Each kinase was diluted to 1 to 10 ng/assay, and ATP was diluted to form a kinase buffer (50 mM HEPES, pH 7.4; 10 mM MgCl 2 ; 1 mM EGTA; and 0.01% BRIJ-35) by calculating an approximate Kd value.
  • the assays were performed in 384-well polystyrene flat-bottomed plates.
  • Peptide substrate having a suitable concentration, 10 ⁇ , of mixed kinase solution and 5 ⁇ , of ATP solution having a concentration of 5 to 300 ⁇ were added to 5 ⁇ of the diluted solution of the compound, and allowed to react in a mixer for 60 minutes at room temperature. After 60 minutes, 10 ⁇ of fluorescent labeling reagents was added to each mixture so as to allow fluorescent labeling of peptide substrates, followed by adding a finishing solution to complete the reaction.
  • the fluorescence level was determined with a Molecular Device at 400 nm (excitation filter) and 520 nm (emission filter).
  • the kinase inhibitory activities of the compounds were calculated in phosphorylation rates between 0-100% against the control group (staurosporine or each of kinase inhibitor) according to the reference protocol of the kit, and percentage inhibition was determine and plotted against concentration (x-axis) to calculate 50% inhibitory concentration (IC 50 ).
  • the calculation and analysis of IC 50 were carried out by using Microsoft Excel. The results are shown in Table 5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE
INHIBITOR
FIELD OF THE INVENTION
The present invention relates to novel triazolopyridine derivatives having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same as an active ingredient.
BACKGROUND OF THE INVENTION
A protein kinase is an enzyme that modifies other proteins by chemically adding phosphate groups to a specific residue thereof via phosphorylation. The human genome contains about 500 protein kinase genes and they constitute about 2% of all human genes. In general, protein kinases can be classified into three types depending on their substrates: serine/threonine-specific protein kinases which phosphorylate serine and/or threonine residues, tyrosine-specific protein kinases which phosphorylate tyrosine residues, and protein kinases which phosphorylate tyrosine and serine/threonine residues. Protein kinases play a key role in mediation of signal transduction from a cell surface to a nucleus in response to a variety of extracellular stimuli. They regulate several physiological and pathological cellular phenomena, including cell division, proliferation, differentiation, apoptosis, cell mobility, mitogenesis, etc., and hence they are closely related with various diseases. Examples of such kinase-related diseases are: autoimmune disorders such as atopic dermatitis, asthma, rheumatoid arthritis, Crohn's disease, psoriasis, Crouzon syndrome, achondroplasia, and thanatophoric dysplasia; cancer such as prostate cancer, colorectal cancer, breast cancer, brain and throat cancer, leukemia and lymphoma; diabetes; restenosis; atherosclerosis; renal and hepatic fibrosis; myeloproliferative disorder and lymphoproliferative disorder; and eye disease. It is known that such diseases are caused directly or indirectly by interruption in kinase regulating mechanism such as mutation, overexpression or abnormal activation of kinase enzyme, and overproduction or underproduction of growth factors or cytokines which affect up-stream or down-stream signaling. Therefore, it is expected that such diseases may be prevented or treated by selectively inhibiting the mechanism of kinase, and thus various attempts have been made to discover an effective protein kinase inhibitor in the fields of medicine and chemistry.
Meanwhile, inflammation is a cause of disease such as rheumatoid arthritis, etc. Continuous attempts have been made to develop an effective medicine to treat inflammation despite the recent discovery of biological treatments. Various evidence has been found which support T-cells (or T- lymphocytes) and B-cells (or B-lymphocytes) play an important role in connection with the outbreak of inflammatory diseases, autoimmune diseases, proliferative or hyper-proliferative diseases and/or immunologically mediated diseases.
Such T-cells mediate signal transduction by receiving signals from antigen-presenting cells through T-cell receptor (TCR) located on the surface of the cell which activates various kinases such as Janus kinase (JA ) so as to forward the signal to effectors. In this regard, JAK proteins, as tyrosine kinases, may be activated by hematopoietic cytokine as well as interferon, and this process can regulate the activation of transcriptional regulators, STAT proteins. Therapeutic possibilities based on the inhibition (or promotion) of JAK/STAT pathway may provide a potent medication in the field of immunomodulation.
Among 4 types of JAK proteins, JAK3 is believed to be implicated in inflammation as it is expressed only in T-cells and activated by IL-2. Unlike JAK2 which participates in hemopoietic activity and red blood cell homeostasis or JAKl which can be expressed in different types of tissues, JAK3 is mostly expressed in lymphocytes and plays a very important role in signaling by using various cytokines including IL-2, IL-4, IL-7, IL-9, IL-15 and the like, and therefore JAK3 is getting more attention in respect of side effects (Flanagan et al., Journal of Medicinal Chemistry, 53, 8468, 2010). According to animal studies, JAK3 plays an important role not only in maturation of B-cells and T-cells, but also in maintenance of functions of T-cells. Therefore, a JAK inhibitor, especially JAK3 inhibitor, may be useful for treatment of autoimmune disorders such as rheumatoid arthritis, psoriasis, atopic dermatitis, lupus, multiple sclerosis, Type I diabetes and diabetic complications, cancer, asthma, thyroid autoimmune disease, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia, etc. as well as various conditions where immunosuppression is required, such as allograft rejection and xenotransplantation (Pesu M, Laurence A, Kishore N, et al., Immunol. Rev, 223, 132, 2008; Kawahara A, Minami Y, Miyazaki T, et al., Proc. Natl. Acad. Sci. USA, 92, 8724, 1995; Nosaka T, van Deursen JMA, Tripp RA, et al., Science, 270, 800, 1995; and Papageorgiou AC, Wikman LEK., et al., Trends Pharm. Sci., 25, 558, 2004)
Meanwhile, Bruton's tyrosine kinase (BTK) is a type of TEC-kinase family which plays an important role in activation of B-cells as well as signal transduction. In 1993, it was discovered that mutations in BTK are related with the major B-cell immune deficiency, i.e., X-linked Agammaglobulinemia (XLA) and mouse X-linked immunodeficiency (XID). It was also discovered that BTK is a nonreceptor protein tyrosine kinase (NRPTK) which participates in controlling signal transduction pathway, growth and differentiation of B- lymphocytes.
BTK is a key regulator of B-cell development, activation, signaling, and survival (Kurosaki, Curr. Op. 1mm., 276-281, 2000; and Schaeffer and Schwartzberg, Curr. Op. lmm., 282-288, 2000]. In addition, BTK plays a role in a number of other hematopoietic cell signaling pathways, e.g., toll-like receptor (TLR)- or cytokine receptor-mediated TNF-a production in macrophages, IgE receptor (FcepsilonRi) signaling in mast cells, inhibition of Fas/APO-1 apoptotic signaling in B-lymphocytes, and collagen-stimulated platelet aggregation.
BTK participates in signal transduction pathways initiated by the binding of a variety of extracellular ligands to their cell surface receptors. After B-cell antigen receptor (BCR) ligation by antigen, BTK activation by the concerted actions of protein tyrosine kinases Lyn and Syk is required for induction of phospholipase C-y2-mediated calcium mobilization (Kurosaki, T., Curr. Opin. Immunol., 9, 309-318, 1997). Therefore, inhibition of BTK can become a useful therapeutic option since it prevents the development of B-cell mediated diseases.
For instance, BTK deficient mice have been shown to be resistant to disease manifestations in collagen-induced arthritis, and BTK inhibitor is known to be effective against collagen-induced arthritis in mice dose-dependently (Jansson and Holmdahl, Clin. Exp. Immunol., 94, 459, 1993; and Pan et al., Chem. Med Chem., 2, 58, 2007). Therefore, an effective BTK inhibitor may be useful for treatment of rheumatoid arthritis.
Further, inhibition of BTK activation can be useful for treatment of autoimmune disease and/or inflammatory disease and/or allergic disease, e.g., systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis, osteoarthritis, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, multiple sclerosis, ankylosing spondylitis, angiitis, inflammatory bowel disease, psoriasis, alopecia universalis, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, allergy, allergic conjunctivitis, allergic rhinitis, atopic dermatitis, and asthma, but not limited thereto. Also, it is known that BTK regulates apoptosis in cells, and hence inhibition of BTK activation can be used to treat B-cell lymphoma and leukemia as well. As explained above, Janus kinases such as JAK3 and TEC kinases such as BTK play important roles in activation of T-cell and/or B-cell that are closely related with development of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproferative diseases and immunologically mediated diseases. Hence, development of an effective inhibitor of such kinases may lead to discovery of potent drug for treatment of various inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, and immunologically mediated diseases.
Currently, Tofacitinib (CP-690550), as an inhibitor of JAK3, is in development as an oral drug by Pfizer and a phase III trial is under way. PCI- 32765 (Pharmacyclics), as an inhibitor of BTK, is in phase I clinical trial stage; however, it has been reported that the drug could activate a different target, accompanied by adverse side effects including skin rash and diarrhea. Therefore, there is a strong need for a novel drug which can inhibit Janus kinases and TEC kinases in a safe and effective manner.
SUMMARY OF THE INVENTION Therefore, it is an object of the present invention to provide a novel compound which inhibits kinases that are mostly expressed in abnormally activated lymphocytes (T- lymphocytes and/or B- lymphocytes) including Janus kinases such as JAK3 as well as TEC kinases such as BTK (Burton's tyrosine kinase), ITK (IL2-inducible T-cell kinase), BMX (bone marrow tyrosine kinase), RLK (resting lymphocyte kinase) and the like.
It is another object of the present invention to provide a pharmaceutical composition comprising the compound for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.
It is a further object of the present invention to provide a method for prevention and treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors by using the compound.
It is a still further object of the present invention to provide a use of the compound for the manufacture of a medicament for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors.
In accordance with one aspect of the present invention, there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof:
Figure imgf000007_0001
wherein,
X is O, NH, CH2, S, SO or SO2;
Y is phenyl or pyridyl;
Figure imgf000007_0002
n is an integer ranging from 0 to 4;
Rl is each independently hydrogen, C1-6alkoxy or di(C]_ 6alkyl)aminomethyl; and
W is phenyl, pyridyl, or phenyl substituted with one or more substituents selected from the group consisting of hydrogen, halogen, hydroxy, amino, C], 6alkylamino, Ci-6alkylheterocyclylamino, di(Ci-6alkyl)aminoCi-6alkyl, heterocycle, hydroxy heterocycle, Ci.6alkylheterocycle, hydroxyC1-6alkylheterocycle, C]. 6alkoxyC1-6alkylheterocycle, heterocyclylcarbonyl, and heterocyclylCt. 6alkylcarbonyl, wherein the heterocycle is a saturated 3- to 8-membered monocyclic hetero ring independently containing one or more of heteroatoms selected from N, O and S.
In accordance with another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors, which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof.
In accordance with a further aspect of the present invention, there is provided a method for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors in an animal, comprising the step of administering to the animal an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
In accordance with a still further aspect of the present invention, there is provided a use of the compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors.
The novel triazolopyridine derivatives in accordance with the present invention can selectively and effectively inhibit kinases that are mostly expressed in abnormally activated lymphocytes (T-lymphocytes and/or B-lymphocytes) including Janus kinases such as JAK3 as well as TEC kinases such as BTK, ITK, BMX and RLK and the like. Therefore, the novel triazolopyridine derivatives as a tyrosine kinase inhibitor in accordance with the present invention may be useful for prevention or treatment of diseases that are mediated by abnormally activated T-lymphocytes, B-lymphocytes or both, such as inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors. DETAILED DESCRIPTION OF THE INVENTION
In formula (I), specific examples of substituent W may be selected from the group consisting of Wl to W18, preferably W2, W4, W9, W12 or W17, but not limited thereto.
Figure imgf000009_0001
W1 W2 W3 W4 W5 W6 W7 W8 W9
Figure imgf000009_0002
W10 W11 W12 W13 W14 W15 W16 W17 W18
The examples of the compounds in accordance with the present invention are as follows:
N-(3-(2-(4-(4-methylpiperazin- 1 -yl)phenylamino)-[ 1 ,2,4]triazolo[ 1,5- a]pyridin-8-yloxy)phenyl)acrylamide; N-(3-(2-(3-fluoro-4-(l-methylpiperidin-4-ylamino)phenylamino)- [ 1 ,2,4]triazolo[ 1 ,5-a]pyridin-8-yloxy)phenyl)acrylamide;
N-(3-(2-(4-((dimethylamino)methyl)phenylamino)-[l,2,4]triazolo[l,5- a]pyridin-8-yloxy)phenyl)acrylamide;
N-(3-(2-(4-(4-methylpiperazin- l-carbonyl)phenylamino)-
[ 1 ,2,4]triazolo[ 1 ,5-a]pyridin-8-yloxy)phenyl)acrylamide; and
N-(3-(2-(4-(4-isopropylpiperazin-l-yl)phenylamino)-[l,2,4]triazolo[l,5- a]pyridin-8-yloxy)phenyl)acrylamide. The compound of formula (I) of the present invention may be prepared by the method shown in Reaction Scheme I as shown below:
<Reaction Scheme I>
Figure imgf000010_0001
(») (8) (7) (6) (5)
CuBr2. NaNO,
HBr
Figure imgf000010_0002
wherein
X, Y, Z and W are the same as defined above.
The reaction processes are exemplified in the following stepwise reaction.
The compound of formula (9) is, for example, subjected to a condensation reaction with the compound of formula (8) under dichloromethane condition to yield a condensed compound of formula (7). Then, hydroxy lamine hydrochloride and diisopropylethylamine may be added to a solvent such as a mixed solvent of methanol and ethanol, followed by addition of the compound of formula (7) prepared above to obtain a compound of formula (6).
Next, the compound of formula (6) is allowed to react with X-Y-NO2 (e.g., 3-fluoronitrobenzene) in an organic solvent such as NN-dimethylformamide, NN-dimethylacetamide or N-methylpyrrolidine in the presence of an inorganic base such as cesium carbonate, sodium carbonate or potassium carbonate at 140 to 150°C with stirring to obtain a compound of formula (5) containing a nitro group. Copper bromide and bromic acid are added to the compound of formula (5), followed by dropwise addition of an aqueous solution of sodium nitrite at -10 to 0°C to obtain a compound of formula (4) containing a bromine group.
The compound of formula (4) prepared above may be reacted with W-NH2 in an organic solvent such as 1 ,4-dioxane in the presence of a palladium catalyst or trifluoroacetic acid at 100 to 110°C for 8 hours with stirring to obtain a compound of formula (3) containing a W-NH2 group.
The nitro group of the compound of formula (3) may be converted to an amino group by subjecting the compound to an iron-mediated reduction reaction or a hydrogenation reaction using palladium/carbon as a catalyst to obtain an aniline compound of formula (2).
Subsequently, the compound of formula (2) may be allowed to react with an acryloyl chloride substituted with Rl in an organic solvent such as dichloromethane or tetrahydrofuran, or a mixed solvent such as an aqueous solution of 50% tetrahydrofuran in the presence of an inorganic base such as sodium bicarbonate or an organic base such as triethylamine or diisopropylethylamine at a low temperature ranging from -10°C to 10°C; or with an acrylic acid substituted with Rl by employing a binder such as l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDCI) or 2-(lH-7-azabenzotriazol-l-yl)- 1,1,3,3-tetramethyl uronium hexafluorophosphate mefhanaminium (HATU) in pyridine, to obtain a desired compound of formula (1) of the present invention containing an acrylamide group.
The compound of formula (I) in the present invention may also form a pharmaceutically acceptable inorganic or organic acid addition salts. Examples of such salts are acid addition salts formed by acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid and the like.
Specifically, the pharmaceutically acceptable salt in the present invention can be prepared by dissolving the compound of formula (I) in a water-miscible organic solvent, e.g., acetone, methanol, ethanol or acetonitrile, followed by adding an organic or inorganic acid, and filtering the precipitated crystal. Also, it may be prepared by removing a solvent or an excessive amount of acid from the acid-added reaction mixture under reduced pressure, followed by drying the residue, or conducting eduction using a different organic solvent, and then filtering the precipitated salt.
The compound of formula (I) or a pharmaceutically acceptable salt thereof in the present invention may be in the form of solvates or hydrates, and such compounds are also included within the scope of the present invention.
The compound of formula (I) or a pharmaceutically acceptable salt thereof in the present invention can selectively and effectively inhibit a protein kinase. In one embodiment, such compound can selectively and effectively inhibit kinases that are mostly expressed in abnormally activated lymphocytes (T- lymphocytes and/or B- lymphocytes) including Janus kinase 3 (JAK3), Bruton's tyrosine kinase (BTK), IL-2 inducing T-cell kinase (ITK), resting lymphocyte kinase (RLK) and bone marrow tyrosine kinase (BMX), and thus, may be useful for prevention or treatment of diseases that are mediated by abnormally activated B-lymphocytes, T-lymphocytes or both, such as inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors.
Therefore, the present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors, which comprises the compound of formula (I) or its pharmaceutically acceptable salt as an active ingredient.
Examples of said inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, or immunologically mediated diseases may be selected from the group consisting of: arthritis, rheumatoid arthritis, spondyloarthropathy, gouty arthritis, osteoarthritis, juvenile arthritis, other arthritic conditions, lupus, systemic lupus erythematosus (SLE), skin-related diseases, psoriasis, eczema, dermatitis, atopic dermatitis, pain, pulmonary disorder, lung inflammation, adult respiratory distress syndrome (ARDS), pulmonary sarcoidosis, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD), cardiovascular disease, artherosclerosis, myocardial infarction, congestive heart failure, cardiac reperfusion injury, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, asthma, Sjogren's syndrome, autoimmune thyroid disease, urticaria, multiple sclerosis, scleroderma, allograft rejection, xenotransplantation, idiopathic thrombocytopenic purpura (ITP), Parkinson's disease, Alzheimer's disease, diabetic associated disease, inflammation, pelvic inflammatory disease, allergic rhinitis, allergic bronchitis, allergic sinusitis, leukemia, lymphoma, B-cell lymphoma, T-cell lymphoma, myeloma, acute lymphoid leukemia (ALL), chronic lymphoid leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), hairy cell leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), diffuse large B-cell lymphoma and follicular lymphoma, but not limited thereto.
Further, examples of said cancer and tumor may be selected from the group consisting of liver cancer, hepatocellular carcinoma, thyroid cancer, colorectal cancer, testicular cancer, bone cancer, oral cancer, basal cell carcinoma, ovarian cancer, brain tumor, gallbladder carcinoma, biliary tract cancer, head and neck cancer, vesical carcinoma, tongue cancer, esophageal cancer, glioma, glioblastoma, renal cancer, malignant melanoma, gastric cancer, breast cancer, sarcoma, pharynx carcinoma, uterine cancer, cervical cancer, prostate cancer, rectal cancer, pancreatic cancer, lung cancer, skin cancer and other solid tumor, but not limited thereto.
The compound of formula (I) or a pharmaceutically acceptable salt thereof in the present invention may be used in combination with other drugs to enhance efficacy in treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, or immunologically mediated diseases.
Examples of the drug which may be used in combination with the inventive compound or a pharmaceutically acceptable salt thereof for treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, or immunologically mediated diseases are one or more of drugs selected from the group consisting of steroids (prednisone, prednisolone, methylprednisolone, cortisone, hydroxycortisone, betamethasone, dexamethasone, etc.), methotrexate, lefluonomide, anti-TNFa agents (etanercept, infliximab, adalimumab, etc.), calcineurin inhibitors (tacrolimus, pimecrolimus, etc.) and anti-histamines (diphenhydramine, hydroxyzine, loratadine, ebastine, ketotifen, cetirizine, levocetirizine, fexofenadine, etc.), but not limited thereto.
Examples of the drug which may be used in combination with the inventive compound or its pharmaceutically acceptable salt for treatment of cancers or tumors include one or more selected from the group consisting of: cell signal transduction inhibitors (glivec, iressa, tarceva, etc.), mitosis inhibitors (vincristine, vinblastine, etc.), alkylating agents (cyclophosphamide, thiotepa, busulfan, etc.), anti-metabolites (tagafur, methotrexate, gemcitabine, etc.), topoisomerase inhibitors (irinotecan, topotecan, amsacrine, etoposide, teniposide, etc.), immunotherapeutic agents (interferon α, β, γ, interleukin, etc.) and anti- hormonal agents (tamoxifen, leuprorelin, anastrozole, etc.), but not limited thereto.
The inventive compound or a pharmaceutically acceptable salt thereof may be administered orally or parenterally as an active ingredient in an effective amount ranging from about 0.1 to 2,000 mg/day, preferably 1 to 1,000 mg/day, 1 to 4 times daily or on/off schedule in case of a human (of approximately 70 kg body weight) in a single dose or in divided doses. The dosage of the active ingredient may be adjusted in light of various relevant factors such as the condition of the subject to be treated, type and seriousness of illness, administration rate, and opinion of doctor. In certain cases, an amount less than the above dosage may be suitable. An amount greater than the above dosage may be used unless it causes deleterious side effects and such amount can be administered in divided doses per day.
The pharmaceutical composition of the present invention may typically comprise pharmaceutically acceptable additives, carriers or excipients. The pharmaceutical composition of the present invention may be formulated in accordance with conventional methods, and may be prepared in the form of oral formulations such as tablets, pills, powders, capsules, syrups, emulsions, microemulsions and others, or parenteral formulations such as intramuscular, intravenous or subcutaneous administrations.
For oral formulations, carriers or additives such as cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspending agents, emulsifiers, diluents, and others may be used. For injectable formulations, carriers or additives such as water, saline, glucose solution, glucose solution analogs, alcohols, glycols, ethers (e.g., polyethylene glycol 400), oils, fatty acids, fatty acid esters, glycerides, surfactants, suspending agents, emulsifiers, and others may be used.
Also, the present invention provides a method for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors in an animal, comprising the step of administering to the animal an effective amount of the compound of formula (I) or its pharmaceutically acceptable salt.
The present invention provides a use of the compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors.
The compound of formula (I) of the present invention may be used for the study of biological and pathological phenomena of a kinase, the study of intracellular signaling pathway mediated by a kinase as well as comparative evaluation with new kinase inhibitors. EXAMPLES
The following Examples are provided to illustrate preferred embodiments of the present invention, and are not intended to limit the scope of the present invention.
Example 1: Preparation of ^-(S-il-i^i^meth lpiperazin-l- phenylamino)- [l,2,4]triazolo[l,5-a]pyridin-8-yloxy)phenyl)acrylamide
Figure imgf000017_0001
Step 1) Preparation of -(3-hvdroxy-2-pyridinyl)-N'-carboethoxy-thiourea
Figure imgf000017_0002
Dichloromethane (100 mL) was added to 2-amino-3-hydroxypyridine (10.0 g, 0.09 lmol). The reaction solution was cooled to 0°C, and ethoxycarbonyl isothiocyanate (1 1.3 mL, 0.1 mol) was added dropwise thereto. The temperature of the mixture was raised to room temperature and the mixture was stirred for 12 hours. A solid formed was cooled to 0°C, washed with 20 mL of dichloromethane, and filtered under reduced pressure. The solid thus obtained was dried under reduced pressure to obtain the title compound (8.4 g, yield: 38%).
Figure imgf000018_0001
A mixed solvent (30 mL) of ethanol and methanol (1 : 1) was added to hydroxylamine hydrochloride (4.6 g, 0.066 mol) at room temperature. Diisopropylethylamine (1 1.6 mL, 0.066 mol) was added to the mixture, followed by stirring for 1 hour. The compound obtained in Step 1 (8.4 g, 0.035 mol) was added to the reaction solution, followed by refluxing for 2 hours at 80 °C or higher. The reaction solution was cooled to 0°C, stirred for 1 hour, and a solid formed was washed with 20 mL of distilled water and filtered under reduced pressure. The solid thus obtained was dried under reduced pressure to obtain the title compound (3.2 g, yield: 54%).
1H-NMR (300 MHz, DMSO-d6) δ 5.80 (s, 2H), 6.68 (m, 2H), 8.01 (d, 1H).
Step 3) Preparation of 8-(3-nitrophenoxy)-[l,2,41triazolori,5-alpyridin-2- amine
Figure imgf000018_0002
N,N-dimethylformamide (30 mL) was added to the compound obtained in Step 2 (3.2 g, 0.021 mol). 3-fluoronitrobenzene (2.7 mL, 0.026 mol) and cesium carbonate (13.9 g, 0.043 mol) was added to the reaction solution. The resulting mixture was stirred for 6 hours at 150°C, and then washed with dichloromethane, distilled water and an aqueous solution of ammonium chloride. The organic layer was separated, dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure. The resulting residue was separated by column chromatography (dichloromethane : methanol = 60 : 1 (v:v)) to obtain the title compound (1.7 g, yield: 30%).
1H-NMR (300 MHz, DMSO-d6) δ 6.14 (s, 2H), 6.94 (t, 1H), 7.35 (d, 2H),7.47 (m, 1H), 7.64 (m 2H), 7.96 (d, 1H), 8.52 (d, 1H).
Step 4) Preparation of 2-bromo-8-(3-nitrophenoxy)-r i,2,41triazolo l,5- a pyridine
Figure imgf000019_0001
Bromic acid (17 mL, 47-49%) was added to a mixture of the compound obtained in Step 3 (1.7 g, 0.006 mol) and copper bromide (0.42 g, 0.002 mol). The reaction solution was cooled to 0°C, and a solution prepared by dissolving sodium nitrite (0.52 g, 0.008 mol) in distilled water (3.5 mL), was added slowly dropwise thereto. The reaction solution was stirred for 15 hours at room temperature, and then washed with dichloromethane, distilled water and an aqueous solution of ammonium chloride. The organic layer was separated, dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure. The resulting residue was separated by column chromatography (dichloromethane : methanol = 40 : 1 (v:v)) to obtain the title compound (1.8 g, yield: 86%).
1H-NMR (300 MHz, DMSO-d6) δ 7.10 (m 2H), 7.48 (m, 1H), 7.60 (t, 1H), 7.90 (m, 1H), 8.06 (dd, 1H), 8.43 (dd, 1H). Step 5) Preparation of N-(4-(4-methylpiperazin- l-yl)phenyl-8-(3-
Figure imgf000020_0001
1,4-dioxane (30 n L) was added to a mixture of the compound obtained in
Step 4 (1.8 g, 0.005 mol) and 4-(4-methylpiperazin-l-yl)aniline (1.03 g, 0.005 mol). Tris(dibenzylideneacetone)dipalladium(0) (0.49 g, 0.001 mol) and 2,2'- bis(diphenylphosphino)-l,l '-binaphthyl (0.33 g, 0.001 mol) were added to the mixture, followed by stirring for 5 minutes at room temperature. Cesium carbonate (3.5 g, 0.011 mol) was added to the reaction mixture, followed by stirring for 8 hours at 100°C. The reaction mixture was cooled to room temperature, filtered through a Celite filter, and the filtrate was diluted with dichloromethane and washed with water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure. The resulting residue was separated by column chromatography (dichloromethane : methanol = 20 : 1 (v:v)) to obtain the title compound (0.91 g, yield: 38%).
1H-NMR (300 MHz, DMSO-d6) δ 2.31 (s, 3H), 2.62 (m, 4H), 3.10 (m, 4H), 6.97 (m, 3H), 7.23 (d, 1H), 7.44 (m, 3H), 7.58 (t, 1H), 7.85 (m, 1H), 8.00 (m, 1H), 8.41 (d, 1H). Step 6) Preparation of 8-(3-aminophenoxy)-N-(4-(4-methylpiperazin-l-
Iron (0.57 g, 0.010 mol) and 12 N aqueous solution of hydrochloric acid (68 μΙ_-, 0.001 mol) were diluted in an aqueous solution of 50% ethanol, followed by stirring for 1 hour at 100°C. The compound obtained in Step 5 (0.91 g, 0.002 mol) was dissolved in an aqueous solution of 50% ethanol (10 mL), added to the reaction flask containing activated iron, followed by stirring for 1 hour at 100°C. The reaction mixture was filtered through a Celite filter so as to remove iron, and the filtrate was distilled under reduced pressure. The residue was diluted with dichloromethane, and washed with an aqueous solution of saturated sodium bicarbonate. The organic layer was separated, dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure. The resulting residue was separated by column chromatography (dichloromethane : methanol = 10 : 1 (v:v)) to obtain the title compound (0.76 g, yield: 90%).
1H-NMR (300 MHz, DMSO-d6) 6 2.21 (s, 3H), 2.44 (m, 4H), 3.02 (m, 4H), 5.22 (s, 2H), 6.18 (m, 2H), 6.32 (m, 1H), 6.99 (m, 4H), 7.12 (d, 1H), 7.52 (d, 2H), 8.57 (d, 1H), 9.38 (s, 1H).
Step 7) Preparation of N-(3-((2-((4-(4-methv iperazin-l- yl)phenvnamino -ri,2,41triazolorL5-alpyridin-8-yl)oxy phenvnacrylamide Tetrahydrofuran (10 mL) and distilled water (2 mL) were added to the compound obtained in Step 6 (0.76 g, 0.002 mol) and sodium bicarbonate (0.46g, 0.006 mol). Acryloyl chloride (0.18 mL, 0.002 mol) was added slowly dropwise to the reaction solution at 0°C, followed by stirring for 2 hours at room temperature. The reaction mixture was diluted with dichloromethane and then washed with an aqueous solution of saturated sodium bicarbonate. The organic layer was separated, dried over anhydrous sodium sulfate, filtered and distilled under reduced pressure. The resulting residue was separated by column chromatography (dichloromethane : methanol = 10 : 1 (v:v)) to obtain the title compound (0.34 g, yield:40%).
Ή-NMR (300 MHz, DMSO-d6) δ 2.22 (s, 3H), 2.50 (m, 4H), 3.03 (m, 4H), 5.73 (dd, 1H), 6.23 (dd, lh), 6.33 (m, 1H), 6.89 (m, 4H), 7.38 (m, 5H), 8.65 (d, 1H), 9.40 (s, 1H), 10.19 (s, 1H).
Example 2: Preparation of 7V-(3-(2-(3-fluoro-4-(l-methylpiperidin-4- ylamino)phenylamino)-[l,2,4]triazolo[l,5-a]pyridin-8- yloxy)phenyI)acrylamide
Figure imgf000022_0001
The procedures of Steps 5, 6 and 7 of Example 1 were repeated in sequence, except for using the compound obtained in Step 4 (0.21 g, about 0.001 mol) and 2-fluoro-N1-(l-methylpiperidin-4-yl)benzene-l,4-diamine (0.14 g, 0.001 mol) to obtain the title compound (0.1 g, yield: 32%).
1H-NMR (300 MHz, DMSO-d6) δ 1.43 (m, IH), 1.82 (m, 2H), 1.95 (m, 2H), 2.15 (s, 3H), 2.72 (m, 2H), 3.13 (m, IH), 4.53 (d, IH), 5.73 (dd, IH), 6.24 (dd, IH), 6.35 (dd, IH), 6.79 (m, 2H), 6.99 (t, IH), 7.12 (dd, IH), 7.40 (m, 5H), 8.66 (d, IH), 9.45 (s, IH), 10.22 (s, IH).
Example 3: Preparation of ΛΓ-(3-(2-(4-
((dimethylamino)methyl)phenylamino)-[l,2,4]triazolo[l,5-a]pyridin-8- yloxy)phenyl)acrylamide
Figure imgf000023_0001
The procedures of Steps 5, 6 and 7 of Example 1 were repeated in sequence, except for using the compound obtained in Step 4 (0.45 g, 0.001 mol) and 4-((dimethylamino)methyl)aniline (0.2 g, 0.001 mol) to obtain the title compound (0.11 g, yield: 23%).
1H-NMR (300 MHz, DMSO-d6) δ 2.10 (s, 6H), 3.28 (s, 2H), 5.73 (dd, IH), 6.24 (dd, IH), 6.33 (dd, IH), 6.80 (dd, IH), 7.00 (t, IH), 7.15 (m, 2H), 7.32 (m, 4H), 7.56 (d, 2H), 8.69 (d, IH), 9.70 (s, IH), 10.22 (s, IH).
Example 4: Preparation of AL(3-(2-(4-(4-methylpiperazin-l- carbonyl)phenylamino)-[l,2,4]triazolo[l,5-a]pyridin-8- yloxy)phenyl)acrylamide
Figure imgf000024_0001
The procedures of Steps 5, 6 and 7 of Example 1 were repeated in sequence, except for using the compound obtained in Step 4 (0.35 g, 0.001 mol) and (4-aminophenyl)(4-methylpiperazin-l-yl)methanone (0.23 g, 0.001 mol) to obtain the title compound (0.13 g, yield: 25%).
Ή-NMR (300 MHz, DMSO-d6) δ 2.19 (s, 3H), 2.30 (m, 4Η), 3.48 (m, 4H), 5.74 (dd, IH), 6.22 (dd, IH), 6.37 (dd, IH), 6.80 (d, IH), 7.04 (t, IH), 7.32 (m, 4H), 7.41 (m, 2H), 7.66 (d, 2H), 8.71 (d, IH), 10.21 (s, IH), 10.29 (s, IH).
Example 5: Preparation of /V-(3-(2-(4-(4-isopropylpiperazin-l- yl)phenylamino)-[l,2,4]tri xy)phenyl)acrylamide
Figure imgf000024_0002
The procedures of Steps 5, 6 and 7 of Example 1 were repeated in sequence, except for using the compound obtained in Step 4 (0.37 g, 0.001 mol) and 4-(4-isopropylpiperazin) (0.24 g, 0.001 mol) to obtain the title compound (0.15 g, yield: 27%).
1H-NMR (300 MHz, DMSO-d6) δ 1.02 (d, 6H), 2.50 (s, 3H), 2.60 (m, 4H), 3.02 (m, 4H), 3.40 (m, 1H), 5.73 (dd, 1H), 6.23 (dd, 1H), 6.33 (m, 1H), 6.89 (m, 4H), 7.38 (m, 5H), 8.64 (d, 1H), 9.41 (s, 1H), 10.19 (s, 1H).
Preparation Example 1: Preparation of Tablet
According to a conventional method, single tablets for oral administration comprising each of the compounds of formula (I) obtained in Examples 1 to 5 as an active ingredient were prepared based on the composition and amount shown in Table 1.
[Table 1]
Figure imgf000025_0001
Preparation Example 2: Preparation of Capsule
According to a conventional method, hard gelatin capsules for oral administration comprising each of the compounds of formula (I) obtained in Examples 1 to 5 as an active ingredient were prepared based on the composition and amount shown in Table 2. [Table 2]
Figure imgf000026_0001
Preparation Example 3: Preparation of Injectable Formulation
According to a conventional method, injectable formulations comprising each of the compounds of formula (I) obtained in Examples 1 to 5 as an active ingredient were prepared based on the composition and amount shown in Table 3, wherein when a salt of the compound of formula (I) was used, the pH value was not adjusted.
[Table 3]
Figure imgf000026_0002
Preparation Example 4: Preparation of Injectable Formulation
According to a conventional method, injectable formulations comprising each of the compounds of formula (I) obtained in Examples 1 to 5 as an active ingredient were prepared based on the composition and amount shown in Table 4.
[Table 4]
Figure imgf000026_0003
Test Example 1 : Evaluation of JAK3 and BTK Inhibitory Activity
The compounds prepared in Examples 1 to 5 were tested for JAK3 and BTK kinase inhibitory activity. Kinase inhibitory activity was measured by using Z-Lyte Kinase Assay Kit (Invitrogen), and JAK3 and BTK enzymes were purchased from Invitrogen (PV3855, PV3190).
Specifically, the compounds of Examples 1 to 5 were diluted with an aqueous solution of 4% DMSO to obtain solutions with concentrations in the range of 1 to 0.0001 μΜ. Each kinase was diluted to 1 to 10 ng/assay, and ATP was diluted to form a kinase buffer (50 mM HEPES, pH 7.4; 10 mM MgCl2; 1 mM EGTA; and 0.01% BRIJ-35) by calculating an approximate Kd value. The assays were performed in 384-well polystyrene flat-bottomed plates. Peptide substrate having a suitable concentration, 10 μΐ, of mixed kinase solution and 5 μΐ, of ATP solution having a concentration of 5 to 300 μΜ were added to 5 μΤ of the diluted solution of the compound, and allowed to react in a mixer for 60 minutes at room temperature. After 60 minutes, 10 μΐ^ of fluorescent labeling reagents was added to each mixture so as to allow fluorescent labeling of peptide substrates, followed by adding a finishing solution to complete the reaction. The fluorescence level was determined with a Molecular Device at 400 nm (excitation filter) and 520 nm (emission filter). The kinase inhibitory activities of the compounds were calculated in phosphorylation rates between 0-100% against the control group (staurosporine or each of kinase inhibitor) according to the reference protocol of the kit, and percentage inhibition was determine and plotted against concentration (x-axis) to calculate 50% inhibitory concentration (IC50). The calculation and analysis of IC50 were carried out by using Microsoft Excel. The results are shown in Table 5. In Table 5, A means IC50 < 100 nM; B means IC50 IC50 = 500-1,000 nM; and D means IC50 > 1,000 nM.
[Table 5]
Figure imgf000028_0001

Claims

WHAT IS CLAIMED IS:
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
Figure imgf000029_0001
wherein,
X is Q, NH, CH2, S, SO or SO2;
Y is phenyl or pyridyl;
Figure imgf000029_0002
n is an integer ranging from 0 to 4;
Rl is each independently hydrogen, C1-6alkoxy or di(C1- 6alkyl)aminomethyl; and
W is phenyl, pyridyl, or phenyl substituted with one or more substituents selected from the group consisting of hydrogen, halogen, hydroxy, amino, Cj. 6alkylamino, C]-6alkylheterocyclylamino, di(C1-6alkyl)aminoCi-6alkyl, heterocycle, hydroxy heterocycle, C1-6alkylheterocycle, hydroxyCi-6alkylheterocycle, d_ 6alkoxyCi-6alkylheterocycle, heterocyclylcarbonyl, and heterocyclylCi. 6alkylcarbonyl, wherein the heterocycle is a saturated 3- to 8-membered monocyclic hetero ring independently containing one or more of heteroatoms selected from N, O and S.
2. The compound of claim 1, wherein W is selected from the group consisting of:
Figure imgf000030_0001
7
Figure imgf000030_0002
3. The compound of claim 1, which is selected from the group consisting of:
N-(3-(2-(4-(4-methylpiperazin- 1 -yl)phenylamino)-[ 1 ,2,4]triazolo[ 1 ,5- a]pyridin-8-yloxy)phenyl)acrylamide;
N-(3-(2-(3-fluoro-4-(l-methylpiperidin-4-ylamino)phenylamino)- [l,2,4]triazolo[l,5-a]pyridin-8-yloxy)phenyl)acrylamide;
N-(3-(2-(4-((dimethylamino)methyl)phenylamino)-[ 1 ,2,4]triazolo[ 1 ,5- a]pyridin-8-yloxy)phenyl)acrylamide;
N-(3-(2-(4-(4-methylpiperazin- 1 -carbonyl)phenylamino)- [l,2,4]triazolo[l,5-a]pyridin-8-yloxy)phenyl)acrylamide; and
N-(3-(2-(4-(4-isopropylpiperazin- 1 -yl)phenylamino)-[ 1 ,2,4]triazolo[ 1 ,5- a]pyridin-8-yloxy)phenyl)acrylamide.
4. A pharmaceutical composition for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors, which comprises the compound of formula (I) or its pharmaceutically acceptable salt of claim 1 as an active ingredient.
5. The pharmaceutical composition of claim 4, wherein the inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors are mediated by one or more of kinases selected from the group consisting of: Janus kinase 3 (JAK3), Bruton's tyrosine kinase (BTK), IL-2 inducing T-cell kinase (ITK), resting lymphocyte kinase (RLK) and bone marrow tyrosine kinase (BMX).
6. The pharmaceutical composition of claim 4, wherein the inflammatory disease, autoimmune disease, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors are mediated by abnormally activated T-lymphocytes, B-lymphocytes or both.
7. The pharmaceutical composition of claim 4, wherein the inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, or immunologically mediated diseases are selected from the group consisting of: arthritis, rheumatoid arthritis, spondyloarthropathy, gouty arthritis, osteoarthritis, juvenile arthritis, other arthritic conditions, lupus, systemic lupus erythematosus (SLE), skin-related diseases, psoriasis, eczema, dermatitis, atopic dermatitis, pain, pulmonary disorder, lung inflammation, adult respiratory distress syndrome (ARDS), pulmonary sarcoidosis, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD), cardiovascular disease, artherosclerosis, myocardial infarction, congestive heart failure, cardiac reperfusion injury, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, asthma, Sjogren's syndrome, autoimmune thyroid disease, urticaria, multiple sclerosis, scleroderma, allograft rejection, xenotransplantation, idiopathic thrombocytopenic purpura (ITP), Parkinson's disease, Alzheimer's disease, diabetic associated disease, inflammation, pelvic inflammatory disease, allergic rhinitis, allergic bronchitis, allergic sinusitis, leukemia, lymphoma, B-cell lymphoma, T-cell lymphoma, myeloma, acute lymphoid leukemia (ALL), chronic lymphoid leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), hairy cell leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, myelodysplasia syndrome (MDS), myeloproliferative neoplasms (MPN), diffuse large B-cell lymphoma and follicular lymphoma.
8. The pharmaceutical composition of claim 4, which further comprises another anticancer agent selected from the group consisting of cell signal transduction inhibitors, mitosis inhibitors, alkylating agents, anti-metabolites, intercalating agents, topoisomerase inhibitors, immunotherapeutic agents, anti- hormonal agents and a mixture thereof as an active ingredient.
9. The pharmaceutical composition of claim 4, which further comprises an additional drug selected from the group consisting of steroids, methotrexate, lefluonomide, anti-TNF a agents, calcineurin inhibitors, anti-histamines and a mixture thereof as an active ingredient.
10. A method for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers, or tumors in an animal, comprising the step of administering to the animal an effective amount of the compound of formula (I) or its pharmaceutically acceptable salt of claim 1.
1 1. A use of the compound of formula (I) or its pharmaceutically acceptable salt of claim 1 for the manufacture of a medicament for preventing or treating inflammatory diseases, autoimmune diseases, proliferative diseases hyperproliferative diseases, immunologically mediated diseases, cancers, tumors.
PCT/KR2013/000539 2012-02-08 2013-01-23 Triazolopyridine derivatives as a tyrosine kinase inhibitor Ceased WO2013118986A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP13747313.8A EP2812335A4 (en) 2012-02-08 2013-01-23 TRIAZOLOPYRIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
CN201380008333.2A CN104093719A (en) 2012-02-08 2013-01-23 Triazolopyridine derivatives as tyrosine kinase inhibitors
CA2862718A CA2862718A1 (en) 2012-02-08 2013-01-23 Triazolopyridine derivatives as a tyrosine kinase inhibitor
US14/376,562 US20140364438A1 (en) 2012-02-08 2013-01-23 Triazolopyridine derivatives as a tyrosine kinase inhibitor
BR112014017701A BR112014017701A8 (en) 2012-02-08 2013-01-23 TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBTOR
AU2013218539A AU2013218539A1 (en) 2012-02-08 2013-01-23 Triazolopyridine derivatives as a tyrosine kinase inhibitor
MX2014009524A MX2014009524A (en) 2012-02-08 2013-01-23 Triazolopyridine derivatives as a tyrosine kinase inhibitor.
JP2014556473A JP2015506974A (en) 2012-02-08 2013-01-23 Triazolopyridine derivatives as tyrosine kinase inhibitors
IN7266DEN2014 IN2014DN07266A (en) 2012-02-08 2013-01-23
HK15102187.2A HK1201824A1 (en) 2012-02-08 2013-01-23 Triazolopyridine derivatives as a tyrosine kinase inhibitor
RU2014136170A RU2014136170A (en) 2012-02-08 2013-01-23 TRIAZOLOPYRIDINE DERIVATIVES AS A TYROZINKINASE INHIBITOR

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120012758A KR20130091464A (en) 2012-02-08 2012-02-08 Triazolopyridine derivatives as a tyrosine kinase inhibitor
KR10-2012-0012758 2012-02-08

Publications (1)

Publication Number Publication Date
WO2013118986A1 true WO2013118986A1 (en) 2013-08-15

Family

ID=48947718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/000539 Ceased WO2013118986A1 (en) 2012-02-08 2013-01-23 Triazolopyridine derivatives as a tyrosine kinase inhibitor

Country Status (13)

Country Link
US (1) US20140364438A1 (en)
EP (1) EP2812335A4 (en)
JP (1) JP2015506974A (en)
KR (1) KR20130091464A (en)
CN (1) CN104093719A (en)
AU (1) AU2013218539A1 (en)
BR (1) BR112014017701A8 (en)
CA (1) CA2862718A1 (en)
HK (1) HK1201824A1 (en)
IN (1) IN2014DN07266A (en)
MX (1) MX2014009524A (en)
RU (1) RU2014136170A (en)
WO (1) WO2013118986A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015032286A1 (en) 2013-09-05 2015-03-12 F.Hoffmann-La Roche Ag Triazolopyridine compounds, compositions and methods of use thereof
WO2017128917A1 (en) 2016-01-29 2017-08-03 北京诺诚健华医药科技有限公司 Parazole condensed-ring derivatives and preparation method thereof and application thereof in treatment of cancers, inflammation and immune diseases
TWI758291B (en) * 2016-05-09 2022-03-21 德商拜耳廠股份有限公司 Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2h)-ones and 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones and use thereof
US20220389010A1 (en) * 2019-11-25 2022-12-08 Daewoong Pharmaceutical Co., Ltd. Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising Same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025821A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
US20090098181A1 (en) * 2005-12-21 2009-04-16 Tianbao Lu Triazolopyridazines as kinase modulators
CA2751517A1 (en) 2009-02-13 2010-08-19 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
US20100298339A1 (en) 2007-10-10 2010-11-25 Cancer Research Technology Limited [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use
US20100311693A1 (en) 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2114900T (en) * 2007-01-31 2019-01-17 Ym Biosciences Australia Pty Thiopyrimidine-based compounds and uses thereof
BR112012033253A2 (en) * 2010-06-23 2016-11-22 Hanmi Science Co Ltd novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098181A1 (en) * 2005-12-21 2009-04-16 Tianbao Lu Triazolopyridazines as kinase modulators
WO2008025821A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
US20100298339A1 (en) 2007-10-10 2010-11-25 Cancer Research Technology Limited [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use
CA2751517A1 (en) 2009-02-13 2010-08-19 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
US20100311693A1 (en) 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2812335A4

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015032286A1 (en) 2013-09-05 2015-03-12 F.Hoffmann-La Roche Ag Triazolopyridine compounds, compositions and methods of use thereof
JP2016529299A (en) * 2013-09-05 2016-09-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Triazolopyridine compounds, compositions thereof and methods of use
EP3041841A4 (en) * 2013-09-05 2017-04-19 F. Hoffmann-La Roche AG Triazolopyridine compounds, compositions and methods of use thereof
US9873709B2 (en) 2013-09-05 2018-01-23 Genentech, Inc. Triazolopyridine compounds, compositions and methods of use thereof
WO2017128917A1 (en) 2016-01-29 2017-08-03 北京诺诚健华医药科技有限公司 Parazole condensed-ring derivatives and preparation method thereof and application thereof in treatment of cancers, inflammation and immune diseases
TWI758291B (en) * 2016-05-09 2022-03-21 德商拜耳廠股份有限公司 Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2h)-ones and 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones and use thereof
US20220389010A1 (en) * 2019-11-25 2022-12-08 Daewoong Pharmaceutical Co., Ltd. Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising Same

Also Published As

Publication number Publication date
KR20130091464A (en) 2013-08-19
US20140364438A1 (en) 2014-12-11
CA2862718A1 (en) 2013-08-15
JP2015506974A (en) 2015-03-05
HK1201824A1 (en) 2015-09-11
CN104093719A (en) 2014-10-08
BR112014017701A8 (en) 2017-07-11
EP2812335A1 (en) 2014-12-17
AU2013218539A1 (en) 2014-07-24
IN2014DN07266A (en) 2015-04-24
EP2812335A4 (en) 2015-07-08
MX2014009524A (en) 2014-09-08
RU2014136170A (en) 2016-03-27
BR112014017701A2 (en) 2017-06-20

Similar Documents

Publication Publication Date Title
RU2598852C2 (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
US20200190126A1 (en) Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)
EP3617213B1 (en) Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases
JP6927994B2 (en) Urea compounds, their production methods and their pharmaceutical uses
US9388165B2 (en) Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase
WO2013100631A1 (en) Novel imidazopyridine derivatives as a tyrosine kinase inhibitor
JP6976248B2 (en) (R) -1- (4- (6- (2- (4- (3,3-difluorocyclobutoxy) -6-methylpyridine-2-yl) acetamide) pyridazine-3-yl) -2-fluorobutyl ) -N-Methyl-1H-1,2,3-triazole-4-carboxamide salt morphology and polymorph
WO2013118986A1 (en) Triazolopyridine derivatives as a tyrosine kinase inhibitor
WO2016115869A1 (en) Novel inhibitor of flt3 kinase and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13747313

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2862718

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013218539

Country of ref document: AU

Date of ref document: 20130123

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013747313

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14376562

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014556473

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 233990

Country of ref document: IL

Ref document number: MX/A/2014/009524

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014017701

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2014136170

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 112014017701

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140718